NCT03182244 2026-02-06
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
49 trialsNCT04240002 2026-01-05
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT03069352 2025-09-30
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT02310321 2025-09-02
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
Phase 1/2 Completed
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT03384654 2025-05-25
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT02038777 2025-02-26
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT01838395 2024-09-19
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
BioLineRx, Ltd.
Phase 2 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT03379727 2024-02-29
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Novartis
Phase 3 Completed
NCT05020665 2024-01-10
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio
Phase 3 Terminated
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT03298984 2023-11-15
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT00804856 2023-10-03
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Boehringer Ingelheim
Phase 2 Completed
NCT03416179 2023-04-21
BRIGHT AML1019
Pfizer
Phase 3 Completed
NCT03303339 2023-02-27
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Cardiff Oncology
Phase 1/2 Completed
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT02287233 2022-08-29
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
AbbVie
Phase 1/2 Completed
NCT02545283 2022-01-11
MIRROS
Hoffmann-La Roche
Phase 3 Terminated
NCT02305563 2021-09-16
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01696084 2020-08-10
301
Jazz Pharmaceuticals
Phase 3 Completed
NCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT01546038 2020-03-03
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Pfizer
Phase 2 Completed
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT00260832 2019-09-11
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Eisai Inc.
Phase 3 Completed
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT00620321 2019-09-09
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Eli Lilly and Company
Phase 2 Completed
NCT01564784 2019-01-09
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 3 Completed
NCT00780143 2018-11-09
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
PharmaMar
Phase 1/2 Terminated
NCT00907517 2018-08-27
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01191801 2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3 Completed
NCT00788892 2018-01-12
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Jazz Pharmaceuticals
Phase 2 Completed
NCT00541866 2018-01-09
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Sunesis Pharmaceuticals
Phase 1/2 Completed
NCT01880437 2015-12-15
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
Hoffmann-La Roche
Phase 2 Terminated
NCT00632749 2015-09-14
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
Boehringer Ingelheim
Phase 2 Completed
NCT00517699 2014-08-08
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Hoffmann-La Roche
Phase 2 Terminated
NCT00317642 2014-04-14
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Sanofi
Phase 3 Completed
NCT00333840 2013-10-14
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis
Phase 3 Completed